Is Japan the Right Market for Your Biotech? A 10-Point Readiness Checklist

Japan is one of the world's largest pharmaceutical markets — and overseas companies already play a significant role in it.

According to JETRO, Japan's pharmaceutical market is the third largest in the world after the United States and China, based on its comparison of prescription drug markets in 2022.

JETRO also estimates that Japan's domestic pharmaceutical market was approximately ¥11.7 trillion (about $78 billion) in 2021.

The Japanese government has introduced initiatives related to new drug discovery, pharmaceutical startups, and the entry of foreign life science companies. PMDA also provides English-language information and consultation pathways for overseas companies considering development in Japan.

For an emerging biotech company, especially at the Series A–C stage, the more useful question is not:

“Is Japan an attractive market?”

It is:

“Is Japan the right market for our company at our current stage?”

Before committing significant resources, it is worth validating whether Japan fits your company's development and commercial strategy.

1. Is there a meaningful unmet need in Japan?

Start with the problem your technology solves.

A strong opportunity in the United States or Europe does not automatically mean the same opportunity exists in Japan.

• How large is the relevant patient population in Japan?
• What is the current standard of care?
• Where are the major gaps in diagnosis or treatment?
• Could demographic, genetic, clinical, or healthcare-system differences affect the opportunity?
• How well is the disease area already served?

The objective is not simply to estimate market size. It is to understand whether your technology addresses a meaningful and commercially relevant need within the Japanese healthcare environment.

2. Do you understand the competitive landscape in Japan?

Many companies begin by looking at their global competitors. That is necessary, but it may not be sufficient.

The relevant landscape in Japan may include:

• Japanese pharmaceutical companies
• Domestic biotech startups
• University spinouts
• Academic research programs
• Competing pipeline assets
• Products already approved or marketed in Japan
• Industry–academia collaborations

Before making a market-entry decision, build a Japan-specific competitive landscape rather than relying solely on a global market report.

3. Does Japan make sense at your current development stage?

“Entering Japan” can mean very different things depending on the company.

For one biotech, it may mean incorporating Japan into a global clinical development program. For another, it may mean identifying a Japanese pharmaceutical company for licensing or co-development.

For an earlier-stage company, the first step might instead be an academic collaboration, research partnership, PoC, or simply testing interest among relevant Japanese organizations.

• Research collaboration
• Clinical development
• Licensing
• Co-development
• Strategic partnership
• Distribution
• Commercialization
• Investment
• Technology validation

4. Have you assessed the regulatory and clinical development pathway?

Regulatory and clinical development feasibility should be considered early.

PMDA provides regulatory information and consultation pathways for companies considering development in Japan.

MHLW has also launched the ENSEMBLExJ One-Stop Service Platform to facilitate the introduction in Japan of products developed by overseas emerging biopharma companies.

This does not mean every overseas biotech needs to become an expert in Japanese regulation. It does mean that regulatory assumptions should be validated before major commitments are made.

5. Is there a viable commercial and reimbursement case?

Regulatory approval and commercial success are different questions.

• What is the addressable patient population?
• What alternatives are currently available?
• How could the product fit into existing clinical workflows?
• What factors could influence adoption?
• What reimbursement considerations could affect the commercial model?
• Would commercialization require a local partner?

A scientifically attractive opportunity may not always translate into a commercially attractive one.

6. Do you know what kind of Japanese partner you actually need?

Companies often say:

“We need a partner in Japan.”

But what kind of partner?

• Pharmaceutical licensing partner
• Co-development partner
• Research collaborator
• CRO
• CDMO
• Distributor
• Commercialization partner
• Academic KOL
• Hospital or clinical research group
• Strategic investor

First define what role a Japanese partner needs to play. Only then does it make sense to build and prioritize a target list.

7. Have you mapped the relevant Japanese stakeholders?

Stakeholder mapping should go deeper than collecting organization names.

Depending on the objective, useful information can include:

• Therapeutic focus
• Technology or modality
• Development pipeline
• Existing partnerships
• Strategic priorities
• International activity
• Potential fit with your technology
• Relevant teams or decision-makers

The real value comes from understanding which organizations matter, why they matter, and which ones should be prioritized.

8. Have you tested whether there is actual local interest?

Before establishing a Japanese entity or making significant local investments, it may be possible to test important assumptions.

• Conversations with Japanese pharmaceutical companies
• Discussions with researchers or KOLs
• Meetings at Japanese life science conferences
• Targeted partner outreach
• Distributor conversations
• PoC or collaboration discussions
• Feedback from potential customers or collaborators

Testing this question before making larger commitments can help reduce uncertainty.

Validate before you build.

9. Can your team operate effectively across language and business contexts?

Japan market entry is not simply a translation exercise.

• Who will research potential Japanese partners?
• Who will handle initial outreach?
• Who will communicate the scientific and commercial value of the technology?
• Who will follow up after meetings?
• Who will communicate Japanese stakeholder feedback to the global team?
• Who will keep potential opportunities moving?

For some Series A–C biotech companies, building a full Japanese team may not yet be necessary.

10. Do you know what success in Japan looks like?

Finally, define the milestone.

• Identifying a focused set of relevant Japanese organizations
• Securing qualified partner conversations
• Identifying potential academic collaborators
• Testing interest among relevant pharmaceutical companies
• Starting a licensing or collaboration discussion
• Assessing clinical development feasibility
• Identifying potential commercialization partners

Defining that milestone before significant investment helps clarify what the initial Japan strategy is intended to achieve.

How Ready Is Your Company for Japan?

Give yourself one point for each question your team can answer with reasonable confidence.

Japan Is a Market to Validate, Not Just Enter

For many emerging biotech companies, the first step may not be “entering Japan.”

It may be validating the opportunity in Japan.

Understand the market. Map the relevant ecosystem. Identify the right stakeholders. Test key assumptions and local interest. Then decide what level of investment makes sense.